Biotech 2050 Podcast
1) Matt Gline, Roivant Sciences CEO, on Clinical Breakthroughs, Capital Discipline & Building Biotech
Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really tak...Show More
2) Jay Hartenbach, President & COO, Diakonos Oncology on Reprogramming Cancer Immunity Breakthrough AI
Synopsis: This episode is proudly sponsored by Quartzy. What happens when engineering discipline, business pragmatism, and breakthrough immunology collide? In this episode of Biotech 2050, host A...Show More
3) John Lepore, CEO & President - ProFound Therapeutics, on Proteome, AI, & Bold First-in-Class Drugs
Synopsis: This episode is proudly sponsored by Quartzy. In this far-reaching conversation, Rahul Chaturvedi speaks with John Lepore, CEO & President of ProFound Therapeutics and CEO-Partner at Flag...Show More
4) Jason Kelly - Ginkgo Bioworks CEO and Co-Founder on Automation, AI Data & Biotech’s Reset
Synopsis: This episode is proudly sponsored by Quartzy. Biotech is undergoing a scientific redesign, and Jason Kelly reveals to host Alok Tayi how automation, AI-ready datasets, and modular lab tec...Show More
5) Arun Swaminathan: Coya CEO on Neuroinflammation, BD Strategy & Patient-Driven Biotech
Synopsis: In a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-effic...Show More
6) How Nimbus CEO Abbas Kazimi Builds Resilient Pipelines Through Culture, Rigor & Smart Bets
Synopsis: Nimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company’s evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. From Werner helicase ...Show More
7) Foresite Capital’s Jim Tananbaum on Biotech Cycles, AI Breakthroughs & Long-Term Value
Synopsis: Jim Tananbaum, Founder & CEO of Foresite Capital, joins Rahul Chaturvedi to dissect the patterns driving biotech innovation, the role of macroeconomic cycles in venture performance, and ho...Show More
8) Geoffrey Duyk, Grove Biopharma CEO, on Polymer Breakthroughs, Intractable Targets & Biotech's Future
Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today’s biotech macro headwinds and building c...Show More
9) Syndax CEO Michael Metzger on Bold Leadership, Dual Drug Launches & Redefining Cancer Care
Synopsis: Few biotechs can pull off what Syndax Pharmaceuticals has achieved — two first-in-class oncology drug launches, built entirely through strategic in-licensing and disciplined execution. In...Show More
10) Co-creating Breakthroughs in R&D: Paul Biondi (Flagship) & Uli Stilz (Novo Nordisk)
Synopsis: When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship...Show More